174 related articles for article (PubMed ID: 29409568)
1. The Effect of Selective c-MET Inhibitor on Hepatocellular Carcinoma in the MET-Active, β-Catenin-Mutated Mouse Model.
Zhan N; Michael AA; Wu K; Zeng G; Bell A; Tao J; Monga SP
Gene Expr; 2018 May; 18(2):135-147. PubMed ID: 29409568
[TBL] [Abstract][Full Text] [Related]
2. Modeling a human hepatocellular carcinoma subset in mice through coexpression of met and point-mutant β-catenin.
Tao J; Xu E; Zhao Y; Singh S; Li X; Couchy G; Chen X; Zucman-Rossi J; Chikina M; Monga SP
Hepatology; 2016 Nov; 64(5):1587-1605. PubMed ID: 27097116
[TBL] [Abstract][Full Text] [Related]
3. The novel ATP-competitive inhibitor of the MET hepatocyte growth factor receptor EMD1214063 displays inhibitory activity against selected MET-mutated variants.
Medová M; Pochon B; Streit B; Blank-Liss W; Francica P; Stroka D; Keogh A; Aebersold DM; Blaukat A; Bladt F; Zimmer Y
Mol Cancer Ther; 2013 Nov; 12(11):2415-24. PubMed ID: 24061647
[TBL] [Abstract][Full Text] [Related]
4. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
[TBL] [Abstract][Full Text] [Related]
5. A selective c-Met and Trks inhibitor Indo5 suppresses hepatocellular carcinoma growth.
Luo T; Zhang SG; Zhu LF; Zhang FX; Li W; Zhao K; Wen XX; Yu M; Zhan YQ; Chen H; Ge CH; Gao HY; Wang L; Yang XM; Li CY
J Exp Clin Cancer Res; 2019 Mar; 38(1):130. PubMed ID: 30885237
[TBL] [Abstract][Full Text] [Related]
6. ABL1, Overexpressed in Hepatocellular Carcinomas, Regulates Expression of NOTCH1 and Promotes Development of Liver Tumors in Mice.
Wang F; Hou W; Chitsike L; Xu Y; Bettler C; Perera A; Bank T; Cotler SJ; Dhanarajan A; Denning MF; Ding X; Breslin P; Qiang W; Li J; Koleske AJ; Qiu W
Gastroenterology; 2020 Jul; 159(1):289-305.e16. PubMed ID: 32171747
[TBL] [Abstract][Full Text] [Related]
7. The novel kinase inhibitor EMD1214063 is effective against neuroblastoma.
Scorsone K; Zhang L; Woodfield SE; Hicks J; Zage PE
Invest New Drugs; 2014 Oct; 32(5):815-24. PubMed ID: 24832869
[TBL] [Abstract][Full Text] [Related]
8. Thyroid Hormone Receptor-β Agonist GC-1 Inhibits Met-β-Catenin-Driven Hepatocellular Cancer.
Puliga E; Min Q; Tao J; Zhang R; Pradhan-Sundd T; Poddar M; Singh S; Columbano A; Yu J; Monga SP
Am J Pathol; 2017 Nov; 187(11):2473-2485. PubMed ID: 28807594
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic potential of N-terminal deletion and S45Y mutant β-catenin in promoting hepatocellular carcinoma development in mice.
Qiao Y; Xu M; Tao J; Che L; Cigliano A; Monga SP; Calvisi DF; Chen X
BMC Cancer; 2018 Nov; 18(1):1093. PubMed ID: 30419856
[TBL] [Abstract][Full Text] [Related]
10. Alpelisib combination treatment as novel targeted therapy against hepatocellular carcinoma.
Xu H; Chen K; Shang R; Chen X; Zhang Y; Song X; Evert M; Zhong S; Li B; Calvisi DF; Chen X
Cell Death Dis; 2021 Oct; 12(10):920. PubMed ID: 34625531
[TBL] [Abstract][Full Text] [Related]
11. Targeting β-catenin in hepatocellular cancers induced by coexpression of mutant β-catenin and K-Ras in mice.
Tao J; Zhang R; Singh S; Poddar M; Xu E; Oertel M; Chen X; Ganesh S; Abrams M; Monga SP
Hepatology; 2017 May; 65(5):1581-1599. PubMed ID: 27981621
[TBL] [Abstract][Full Text] [Related]
12. β-catenin deficiency in hepatocytes aggravates hepatocarcinogenesis driven by oncogenic β-catenin and MET.
Liang Y; Feng Y; Zong M; Wei XF; Lee J; Feng Y; Li H; Yang GS; Wu ZJ; Fu XD; Feng GS
Hepatology; 2018 May; 67(5):1807-1822. PubMed ID: 29152756
[TBL] [Abstract][Full Text] [Related]
13. Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma.
Shang R; Song X; Wang P; Zhou Y; Lu X; Wang J; Xu M; Chen X; Utpatel K; Che L; Liang B; Cigliano A; Evert M; Calvisi DF; Chen X
Gut; 2021 Sep; 70(9):1746-1757. PubMed ID: 33144318
[TBL] [Abstract][Full Text] [Related]
14. Nuclear factor erythroid 2-related factor 2 and β-Catenin Coactivation in Hepatocellular Cancer: Biological and Therapeutic Implications.
Tao J; Krutsenko Y; Moghe A; Singh S; Poddar M; Bell A; Oertel M; Singhi AD; Geller D; Chen X; Lujambio A; Liu S; Monga SP
Hepatology; 2021 Aug; 74(2):741-759. PubMed ID: 33529367
[TBL] [Abstract][Full Text] [Related]
15. Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma.
Bouattour M; Raymond E; Qin S; Cheng AL; Stammberger U; Locatelli G; Faivre S
Hepatology; 2018 Mar; 67(3):1132-1149. PubMed ID: 28862760
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma.
Teufel M; Seidel H; Köchert K; Meinhardt G; Finn RS; Llovet JM; Bruix J
Gastroenterology; 2019 May; 156(6):1731-1741. PubMed ID: 30738047
[TBL] [Abstract][Full Text] [Related]
17. Trends in the development of MET inhibitors for hepatocellular carcinoma.
Okuma HS; Kondo S
Future Oncol; 2016 May; 12(10):1275-86. PubMed ID: 26984595
[TBL] [Abstract][Full Text] [Related]
18. Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression.
Decaens T; Barone C; Assenat E; Wermke M; Fasolo A; Merle P; Blanc JF; Grando V; Iacobellis A; Villa E; Trojan J; Straub J; Bruns R; Berghoff K; Scheele J; Raymond E; Faivre S
Br J Cancer; 2021 Jul; 125(2):190-199. PubMed ID: 33824476
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic efficacy of FASN inhibition in preclinical models of HCC.
Wang H; Zhou Y; Xu H; Wang X; Zhang Y; Shang R; O'Farrell M; Roessler S; Sticht C; Stahl A; Evert M; Calvisi DF; Zeng Y; Chen X
Hepatology; 2022 Oct; 76(4):951-966. PubMed ID: 35076948
[TBL] [Abstract][Full Text] [Related]
20. Complete response of Ctnnb1-mutated tumours to β-catenin suppression by locked nucleic acid antisense in a mouse hepatocarcinogenesis model.
Delgado E; Okabe H; Preziosi M; Russell JO; Alvarado TF; Oertel M; Nejak-Bowen KN; Zhang Y; Monga SP
J Hepatol; 2015 Feb; 62(2):380-7. PubMed ID: 25457204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
